AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34378199 — intervention group
Group type: EXPERIMENTAL
Intervention: LA ultrasound feature and AF duration
Number of subjects: 0
Study 32618252 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) and focal MDA (fMDA)
Number of subjects: 0
Study 33821999 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Led Transitional Care Model
Number of subjects: 66
Study 33821999 — intervention group
Group type: COMPARATOR
Intervention: Standard care services
Number of subjects: 66
Study 32683384 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual-based four-cornered flap (Group A)
Number of subjects: 17
Study 32683384 — intervention group
Group type: COMPARATOR
Intervention: Conventional triangular flap (Group B)
Number of subjects: 17
Study 33191772 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA (1.8 g daily)
Number of subjects: 1027
Study 33191772 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 1027
Study 33176824 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous veno-venous hemodialysis with high cutoff dialyzer
Number of subjects: 70
Study 33176824 — intervention group
Group type: COMPARATOR
Intervention: Continuous veno-venous hemodiafiltration with high-flux dialyzer
Number of subjects: 70
Study 33176824 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 70
Study 32478459 — intervention group
Group type: EXPERIMENTAL
Intervention: CoCr-DP-EES
Number of subjects: 5446
Study 32478459 — intervention group
Group type: EXPERIMENTAL
Intervention: PtCr-DP-EES
Number of subjects: 5446
Study 32478459 — intervention group
Group type: EXPERIMENTAL
Intervention: PtCr-BP-EES
Number of subjects: 5446
Study 32478459 — intervention group
Group type: EXPERIMENTAL
Intervention: CoCr-DP-EES (in complex PCI)
Number of subjects: 5446
Study 32478459 — intervention group
Group type: EXPERIMENTAL
Intervention: PtCr-DP-EES (in complex PCI)
Number of subjects: 5446
Study 32478459 — intervention group
Group type: EXPERIMENTAL
Intervention: PtCr-BP-EES (in complex PCI)
Number of subjects: 5446
Study 36075387 — intervention group
Group type: EXPERIMENTAL
Intervention: IPCA hydromorphone with bolus‐only dose (A1)
Number of subjects: 95
Study 36075387 — intervention group
Group type: EXPERIMENTAL
Intervention: IPCA hydromorphone with continuous infusion (A2)
Number of subjects: 95
Study 36075387 — intervention group
Group type: COMPARATOR
Intervention: Oral extended‐release morphine (B)
Number of subjects: 95
Study 34350902 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Help Plus (SH+)
Number of subjects: 459
Study 35228117 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy plus standardised medical care (CBT+SMC)
Number of subjects: 0
Study 32720188 — intervention group
Group type: EXPERIMENTAL
Intervention: Samata intervention
Number of subjects: 1840
Study 33378117 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative theory about buoyancy (Explanation-First)
Number of subjects: 96
Study 33378117 — intervention group
Group type: COMPARATOR
Intervention: Anomalies (Anomalies-First)
Number of subjects: 96
Study 35112219 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) + Vitamin B12 + Magnesium (Supp)
Number of subjects: 60
Study 35112219 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 60
Study 35112219 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B12 + Magnesium (Supp)
Number of subjects: 60
Study 32513290 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE) administered using the Spectra Optia TM Apheresis System, first dose of 1.5 plasma volumes followed by one plasma volume on alternate days or daily for five to seven total treatments.
Number of subjects: 120
Study 32513290 — intervention group
Group type: COMPARATOR
Intervention: Usual empiric treatment for COVID-19 without TPE.
Number of subjects: 120
Study 35022874 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection (40 mg of triamcinolone acetate solution applied to carpal tunnel)
Number of subjects: 87
Study 35022874 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) (applied five times a week for a total of 15 sessions, fluence of 6 j/cm2 for 1 min per point at a wavelength of 830 nm)
Number of subjects: 87
Study 35022874 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 87
Study 35022874 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 87
Study 35022874 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Corticosteroid and LLLT)
Number of subjects: 87
Study 35022874 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection and LLLT
Number of subjects: 87
Study 34562208 — intervention group
Group type: EXPERIMENTAL
Intervention: AlphaWave® l-Theanine (200 mg)
Number of subjects: 0
Study 34562208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36197349 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAPPS lecture
Number of subjects: 26
Study 36197349 — intervention group
Group type: COMPARATOR
Intervention: Traditional case presentation (control)
Number of subjects: 26
Study 34302449 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg TERN-101 capsules
Number of subjects: 38
Study 34302449 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg TERN-101 capsules
Number of subjects: 38
Study 34302449 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg TERN-101 capsules
Number of subjects: 38
Study 34302449 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg TERN-101 tablets
Number of subjects: 38
Study 34302449 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg TERN-101 tablets
Number of subjects: 38
Study 34302449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 32461104 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant immune checkpoint blockade (ICB)
Number of subjects: 149
Study 32461104 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab treatment arm
Number of subjects: 149
Study 32461104 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment arm
Number of subjects: 149
Study 32461104 — intervention group
Group type: EXPERIMENTAL
Intervention: High TMB and immune gene expression profile (GEP)
Number of subjects: 149
Study 32461104 — intervention group
Group type: EXPERIMENTAL
Intervention: Low TMB and immune gene expression profile (GEP)
Number of subjects: 149
Study 34582323 — intervention group
Group type: EXPERIMENTAL
Intervention: MenABCWY vaccine (0-2, 0-6, 0-2-6, 0-1, or 0-11 month schedule)
Number of subjects: 0
Study 34582323 — intervention group
Group type: COMPARATOR
Intervention: 4CMenB vaccine (0-2 month schedule)
Number of subjects: 0
Study 35356991 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐irradiance photodynamic therapy combined with Er:YAG pretreatment (18.5 mW/cm2)
Number of subjects: 0
Study 35356991 — intervention group
Group type: COMPARATOR
Intervention: Conventional photodynamic therapy (61.67 mW/cm2)
Number of subjects: 0
Study 35356991 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐irradiance photodynamic therapy combined with Er:YAG pretreatment
Number of subjects: 0
Study 34247932 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal administration of recombinant human heparan-N-sulfatase (rhHNS) 45 mg
Number of subjects: 17
Study 34247932 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 17
Study 35028701 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise (PFME) with a vaginal cone at home (n = 20)
Number of subjects: 40
Study 35028701 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise (PFME) with EMG biofeedback in the hospital (n = 20)
Number of subjects: 40
Study 35028701 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 40
Study 33486526 — intervention group
Group type: EXPERIMENTAL
Intervention: JUUL System 59 mg/mL
Number of subjects: 24
Study 33486526 — intervention group
Group type: EXPERIMENTAL
Intervention: JUUL System 18 mg/mL
Number of subjects: 24
Study 33486526 — intervention group
Group type: EXPERIMENTAL
Intervention: JUUL System 9 mg/mL
Number of subjects: 24
Study 33486526 — intervention group
Group type: COMPARATOR
Intervention: Usual Brand (UB) cigarettes
Number of subjects: 24
Study 34883040 — intervention group
Group type: EXPERIMENTAL
Intervention: Premium hearing aids
Number of subjects: 23
Study 34883040 — intervention group
Group type: COMPARATOR
Intervention: Entry-level hearing aids
Number of subjects: 23
Study 32359666 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-administered SBIRT
Number of subjects: 0
Study 32359666 — intervention group
Group type: EXPERIMENTAL
Intervention: e-SBIRT
Number of subjects: 0
Study 32359666 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 0
Study 35648674 — intervention group
Group type: EXPERIMENTAL
Intervention: MusiCure music before and during colonoscopy
Number of subjects: 337
Study 35648674 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no music)
Number of subjects: 337
Study 32297783 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg lisdexamfetamine dimesylate
Number of subjects: 20
Study 32297783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 32589449 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicines (CHMs)
Number of subjects: 52
Study 32589449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing clinical trials of CHM interventions
Number of subjects: 52
Study 32589449 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trials of CHMs
Number of subjects: 52
Study 32589449 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size of ongoing trials
Number of subjects: 52
Study 33775153 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person prolonged exposure therapy
Number of subjects: 151
Study 33775153 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine prolonged exposure therapy
Number of subjects: 151
Study 33775153 — intervention group
Group type: COMPARATOR
Intervention: Both treatment conditions (in-person and telemedicine)
Number of subjects: 151
Study 34256133 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 2 (40 g kg−1 WMRP)
Number of subjects: 320
Study 34256133 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 3 (108 CFU g−1 LP)
Number of subjects: 320
Study 34256133 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 4 (40 g kg−1 WMRP + 108 CFU g−1 LP)
Number of subjects: 320
Study 34256133 — intervention group
Group type: COMPARATOR
Intervention: Control (Diet 1: 0 g kg−1 WMRP and 0 CFU g−1 L. plantarum)
Number of subjects: 320
Study 34432975 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E (vaccine)
Number of subjects: 6861
Study 34432975 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine and amodiaquine (chemoprevention)
Number of subjects: 6861
Study 34432975 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of RTS,S/AS01E and chemoprevention
Number of subjects: 6861
Study 34432975 — intervention group
Group type: COMPARATOR
Intervention: Combination vs Chemoprevention
Number of subjects: 6861
Study 34432975 — intervention group
Group type: COMPARATOR
Intervention: Combination vs Vaccine
Number of subjects: 6861
Study 33103954 — intervention group
Group type: EXPERIMENTAL
Intervention: micro-LED device (group aBL) for 3 and 7 days
Number of subjects: 30
Study 33103954 — intervention group
Group type: COMPARATOR
Intervention: calcium hydroxide (group CH) for 3 and 7 days
Number of subjects: 30
Study 33103954 — intervention group
Group type: COMPARATOR
Intervention: normal saline (group NS) for 3 and 7 days
Number of subjects: 30
Study 33103954 — intervention group
Group type: EXPERIMENTAL
Intervention: continuous low-level aBL exposure
Number of subjects: 30
Study 33553973 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule FMT
Number of subjects: 40
Study 33553973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 33553973 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics+enema FMT
Number of subjects: 40
Study 33553973 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 40
Study 35813432 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioception and balance training combined with continuous nursing
Number of subjects: 60
Study 35813432 — intervention group
Group type: COMPARATOR
Intervention: Continuous nursing
Number of subjects: 60
Study 33587500 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine
Number of subjects: 134
Study 33587500 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir Alafenamide-based regimens
Number of subjects: 134
Study 32711855 — intervention group
Group type: COMPARATOR
Intervention: High LCSB consumers (≥12 servings/wk)
Number of subjects: 476
Study 32711855 — intervention group
Group type: COMPARATOR
Intervention: Decrease in LCSB consumption
Number of subjects: 476
Study 32711855 — intervention group
Group type: COMPARATOR
Intervention: Change in LCSB intake
Number of subjects: 476
Study 32711855 — intervention group
Group type: EXPERIMENTAL
Intervention: LCSB consumption
Number of subjects: 476
Study 34487167 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Brains-Fitbit (AB-F) for 8 weeks
Number of subjects: 19
Study 34487167 — intervention group
Group type: COMPARATOR
Intervention: Health Enhancement Program (HEP) educational control for 8 weeks
Number of subjects: 19
Study 33625196 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral Ganglion (SG) frequency-to-place map
Number of subjects: 11
Study 33625196 — intervention group
Group type: COMPARATOR
Intervention: Organ of Corti (OC) place-based map
Number of subjects: 11
Study 34971577 — intervention group
Group type: EXPERIMENTAL
Intervention: Itacitinib plus corticosteroids
Number of subjects: 439
Study 34971577 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus corticosteroids
Number of subjects: 439
Study 34190405 — intervention group
Group type: EXPERIMENTAL
Intervention: PediCARE intervention (providing transportation and groceries)
Number of subjects: 9
Study 32967513 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized psychological interventions, routine nursing care and drug treatment
Number of subjects: 438
Study 32967513 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care and drug treatment
Number of subjects: 438
Study 32967513 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (observation and control)
Number of subjects: 438
Study 35337884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooking/Serving Resources and Meal Delivery
Number of subjects: 499
Study 35337884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooking/Serving Resources
Number of subjects: 499
Study 35337884 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal Delivery
Number of subjects: 499
Study 34758385 — intervention group
Group type: EXPERIMENTAL
Intervention: Precoding
Number of subjects: 1205
Study 35263346 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 minute therapy dog team visit in addition to usual care
Number of subjects: 97
Study 35263346 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy dog visit)
Number of subjects: 97
Study 37019580 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity statin with ezetimibe combination therapy
Number of subjects: 3780
Study 37019580 — intervention group
Group type: COMPARATOR
Intervention: High-intensity statin monotherapy
Number of subjects: 3780
Study 36241842 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus fluorouracil and cisplatin (FP)
Number of subjects: 0
Study 36241842 — intervention group
Group type: COMPARATOR
Intervention: Blended chemotherapy (including FP, carboplatin plus paclitaxel, FOLFOX, FOLFIRI, docetaxel plus FP, trastuzumab plus FP, and trastuzumab plus FOLFOX)
Number of subjects: 0
Study 32217842 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient Hyaluronic Acid Fillers
Number of subjects: 174
Study 32217842 — intervention group
Group type: COMPARATOR
Intervention: Comparator HA filler
Number of subjects: 174
Study 34962457 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU every 2 weeks for 24 weeks)
Number of subjects: 60
Study 34962457 — intervention group
Group type: COMPARATOR
Intervention: Placebo (every 2 weeks for 24 weeks)
Number of subjects: 60
Study 34418716 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 100
Study 34418716 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral vapocoolant spray
Number of subjects: 100
Study 34418716 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral vapocoolant spray
Number of subjects: 100
Study 34418716 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine digital block process)
Number of subjects: 100
Study 33460301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast treatment
Number of subjects: 255
Study 33460301 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (control)
Number of subjects: 255
Study 35390320 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 80
Study 35390320 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 80
Study 34022170 — intervention group
Group type: COMPARATOR
Intervention: Pooled population-based studies (no antiplatelet therapy)
Number of subjects: 674
Study 34022170 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobar ICH
Number of subjects: 674
Study 34022170 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 674
Study 34022170 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobar ICH without AF
Number of subjects: 674
Study 32833763 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D display technique
Number of subjects: 128
Study 35349397 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced solution (Plasma‐Lyte 148)
Number of subjects: 10520
Study 35349397 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 10520
Study 32918078 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 half-hour telephone sessions (n = 162)
Number of subjects: 322
Study 32918078 — intervention group
Group type: COMPARATOR
Intervention: newsletter control (n = 160)
Number of subjects: 322
Study 32918078 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 322
Study 35971295 — intervention group
Group type: EXPERIMENTAL
Intervention: Active HF-rTMS
Number of subjects: 80
Study 35971295 — intervention group
Group type: COMPARATOR
Intervention: Sham HF-rTMS
Number of subjects: 80
Study 35436797 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective, clopidogrel-based therapy (unguided de-escalation)
Number of subjects: 11006
Study 35436797 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective, clopidogrel-based therapy (guided clopidogrel therapy)
Number of subjects: 11006
Study 35436797 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective, clopidogrel-based therapy (overall)
Number of subjects: 11006
Study 35436797 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (ticagrelor or prasugrel)
Number of subjects: 11006
Study 32285142 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin + dexamethasone sodium phosphate (L-DSP) eye drops
Number of subjects: 125
Study 32285142 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (L) eye drops
Number of subjects: 125
Study 32285142 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone sodium phosphate (DSP) eye drops
Number of subjects: 125
Study 33772862 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) initiated within 30 days of diagnosis
Number of subjects: 16
Study 32305105 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse shoulder arthroplasty with latissimus dorsi and teres major tendon transfer
Number of subjects: 0
Study 32305105 — intervention group
Group type: COMPARATOR
Intervention: Reverse shoulder arthroplasty without tendon transfer
Number of subjects: 0
Study 35534184 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (cumulative dose 72.5 mg/kg)
Number of subjects: 372
Study 35534184 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 372
Study 34404384 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 mcg/kg intravenous
Number of subjects: 24
Study 34404384 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 mcg/kg intravenous
Number of subjects: 24
Study 34404384 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 24
Study 32924076 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute psychological stress induced by displaying a brief stressful movie clip
Number of subjects: 88
Study 32924076 — intervention group
Group type: COMPARATOR
Intervention: Neutral movie clip
Number of subjects: 88
Study 34195809 — intervention group
Group type: EXPERIMENTAL
Intervention: Rule-out profile based on the 0/1-h high-sensitivity cardiac troponin T protocol (<5 ng/L or ≤12 ng/L and a change of <3 ng/L at 1-h)
Number of subjects: 1638
Study 34195809 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of clinical risk scores (TIMI, HEART, EDACS) to the rule-out profile
Number of subjects: 1638
Study 33362221 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS)
Number of subjects: 1609
Study 33362221 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements with 50% milk protein
Number of subjects: 1609
Study 33362221 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements with 20% milk protein in CSB
Number of subjects: 1609
Study 33362221 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isolate over dehulled soy
Number of subjects: 1609
Study 33362221 — intervention group
Group type: COMPARATOR
Intervention: Lipid-based nutrient supplements (LNS) vs Corn-soy blends (CSB)
Number of subjects: 1609
Study 36008814 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase + methotrexate (15 mg/week) and folic acid (1 mg/day) administered 4 weeks before and during pegloticase therapy.
Number of subjects: 14
Study 36008814 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase + methotrexate
Number of subjects: 14
Study 35162891 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure on the Shenmen and Neiguan acupoints
Number of subjects: 100